Related Experiment Video

Updated: Aug 10, 2026

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
06:03

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery

Published on: September 30, 2021

[Continuous subcutaneous insulin infusion in pediatric patients with type 1 diabetes mellitus]

E Colino Alcol1, M López Capapé, María A Alvarez Gómez

  • 1Servicio de Pediatría, Hospital Ramón y Cajal, Madrid, Spain.

Anales De Pediatria (Barcelona, Spain : 2003)
|March 17, 2006
PubMed

Insights

Continuous subcutaneous insulin infusion therapy effectively manages type 1 diabetes in pediatric patients. This treatment improves glycemic control and reduces severe hypoglycemia episodes, offering a safe alternative for children and adolescents.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Context:

  • Type 1 diabetes mellitus (T1DM) presents unique challenges in pediatric populations.
  • Optimizing glycemic control and minimizing complications are crucial in managing T1DM in children and adolescents.
  • Continuous subcutaneous insulin infusion (CSII) therapy offers a potential advancement in T1DM management.

Purpose:

  • To evaluate the efficacy and safety of CSII therapy in pediatric patients with T1DM.
  • To assess changes in glycemic control (HbA1c), body mass index (BMI), and insulin dosage.
  • To compare the incidence of severe hypoglycemic episodes and diabetic ketoacidosis (DKA) before and after CSII initiation.

Summary:

  • A study involving 17 pediatric patients with T1DM demonstrated significant improvements in metabolic control.
  • HbA1c levels decreased from 8.12% to 7.52% within the first year of CSII therapy.
  • CSII therapy led to a reduction in insulin dosage and a notable decrease in severe hypoglycemic events, with minimal DKA incidence.

Impact:

  • CSII therapy is a safe and effective treatment option for children and adolescents with T1DM.
  • Improved metabolic control and reduced hypoglycemia enhance the quality of life for young patients.
  • This study supports the broader adoption of CSII in pediatric diabetes care.
Abstract

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice06:57

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice

Published on: April 10, 2026

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...